Drug companies take the initiative to reduce prices or become a new normal

Source: 21st century economic report 2017-05-08 at present, drug bidding and purchase season is coming in all over the country, and the successful news of drug price bargaining is frequently heard from all provinces, but some drug companies take the initiative to apply for price reduction According to the statistics of the insiders, up to 2017, there have been 3 manufacturers (Roche, Zhengda Tianqing and a Belgian pharmaceutical company) and 5 pharmaceutical companies with product specifications actively applied for price reduction, of which the decline of Belgian pharmaceutical companies has reached 47% As for the price reduction, the person in charge of Zhengda Tianqing told the 21st century economic report: "Zhengda Tianqing has always supported and cooperated with the government's policies and measures to deepen the reform of the medical system, so as to reduce the drug burden of patients It is hoped that this move will improve the accessibility and affordability of the drug, and at the same time, it is hoped that this price adjustment will drive the growth of product sales " Shi lichen, founder of the third-party medical service system, pointed out that in the future, pharmaceutical companies will take the initiative to reduce prices or become a new normal, which is the combination of national supporting boxing, including the launch of national negotiations on the medical insurance catalog, the governance of pharmaceutical representatives to combat commercial bribery, and the enhancement of generic evaluation to improve drug quality "The national policy situation is very clear, and pharmaceutical enterprises should comply with the policy development and can no longer wait and see." Pharmaceutical companies' abacus when some pharmaceutical companies are worried about the "price reduction" of drugs in the provincial bidding, Roche, Zhengda Tianqing and other pharmaceutical companies choose to apply for price reduction actively According to the statistics of insiders, up to now, 3 manufacturers and 5 specifications have applied for price reduction actively The prices of drug companies with lower prices are as follows: the bid winning prices of two different dosage forms of pailuoxin injection for adult chronic hepatitis of Roche are 835 yuan and 1055.53 yuan respectively, and the adjusted prices are 798 yuan and 995 yuan respectively; the bid winning prices of two dosage forms of Zhengda Tianqing anti-tumor drug genico capsule are 246.09 yuan and 1259 yuan respectively, and the adjusted prices are 185 yuan and 872.19 yuan respectively; the bid winning prices of Belgium besins manufac turing The price of Belgium in the treatment of estrogenic gel caused by estrogen deficiency is 87.85 yuan, and the adjusted price is 46.61 yuan In response, the head of Zhengda Tianqing explained to the 21st century economic reporter that this is in line with the national policies and measures to deepen the reform of the medical system and reduce the drug burden of patients "Zhengda Tianqing hopes to drive the growth of product sales through this price adjustment With the continuous improvement of imatini's market share and the expansion of product capacity, the cost also decreases Therefore, price adjustment is also in line with the normal market law " According to reports, the price adjusted genico (general name: imatinib mesylate capsule) is an oral tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) in the acute, accelerated or chronic phase of failure of α - interferon treatment It is a first-line drug for the treatment of chronic myeloid leukemia (CML), which can make the 10-year survival rate of CML patients 85% - 90% In fact, there are not many drug companies that take the initiative to reduce their prices in the bidding process A head of a multinational drug company once told 21st century economic news that they have been in China for many years, even when the original research drugs expire, they will not easily reduce their prices, because there is enough market space to support them, and there is little competition for domestic generic drugs However, after GSK announced a 30% reduction in the price of the best-selling hepatitis B drugs in 2015, with the adjustment of relevant national policies, multinational pharmaceutical companies began to take the initiative to reduce the price For example, on July 5, 2016, the terminal price of the heavy-duty product of Novartis Pharma in China, Leizhu MAb (noside), was reduced from 9800 yuan / piece to 7200 yuan / piece, and the price of each piece was reduced by 2600 yuan, a drop of 26% In the second half of 2016, Roche took the initiative to reduce its price by 30% On May 20, 2016, the national health and Family Planning Commission released the list of the first batch of national drug price negotiations, and troika, who had been shortlisted for negotiations, did not appear on the list Roche said that, as the first enterprise to participate in the first round of drug price negotiation, although it was ultimately out of the game because the price reduction rate was lower than other participants, the communication between the enterprise and the health and Family Planning Commission was not interrupted There are both multinational and domestic pharmaceutical companies that actively reduce prices or become new normal In the view of Mr Shi lichen, founder of the third-party medical service system, this kind of active price reduction will present a new normal, especially in large pharmaceutical companies, tumor drugs "Multinational pharmaceutical enterprises participate in the negotiation in order to exchange the price reduction for the opportunity to enter the medical insurance catalog, which has a great pulling effect on the promotion of drug sales; domestic generic pharmaceutical enterprises also hope to compete with the original research drugs and expand sales through price advantage." At present, the purpose of drug companies' active price reduction is to exchange price for quantity, which is a consensus reached in the industry Liu Qian, a senior analyst in the pharmaceutical industry, pointed out that the national health insurance budget is limited, and the way to enter the health insurance is to increase the price drop It is reported that in 2012-2016, as many as 631 patent drugs expired in the world, 18 of the top 20 best-selling prescription drugs will expire, and the "cliff" of foreign patent drugs has arrived Therefore, subject to the slowdown of sales growth, more foreign pharmaceutical enterprises will enter into the price negotiation mechanism Domestic pharmaceutical companies are also facing fierce competition in generic drugs, one original drug or a dozen generic drugs In the view of the insiders, if a generic drug enters the medical insurance, the sales volume will be guaranteed, and it will occupy an advantage in the competition with other generic drugs, and even compete with the original research drug According to the introduction of the relevant person in charge of the Ministry of human resources and social security at the end of April, the scope of 2017 medical insurance negotiation catalog has finally determined 44 varieties Currently, a negotiation plan is being formulated to complete this negotiation in the first half of the year, nearly half of which are tumor targeted drugs, covering the drugs for common tumors, cardiovascular and cerebrovascular diseases and other major diseases According to Li Ting, a researcher of gotega investment, tumor drugs will be listed in the first batch of national health insurance negotiation In the field of tumor treatment, there will be a "big variety" with an annual terminal sales of more than 4 billion yuan, just like in the field of cardio cerebrovascular Dong Chaohui, deputy director of the Medical Insurance Research Office of the Social Security Research Institute of the Ministry of human resources and social security, pointed out that with the initial establishment of universal medical insurance, medical insurance payment institutions will become the main sales channel of most drugs, which is likely to affect drug prices In fact, since 1996, China's pharmaceutical industry has experienced 32 overall forced price reductions, but all of them ended in failure Shi lichen, founder of the third-party medical service system, pointed out that this was mainly because there was no linkage between departments At present, the government is fighting a combination of boxing, multi sector linkage During the "two sessions" in 2016, the "coordinated promotion of medical care, medical insurance and medical linkage reform" was written into the government work report for the first time For example, the current two vote system means that all departments work together, which is jointly implemented by the medical reform office of the State Council, the national health and Family Planning Commission and other eight departments Among them, consistency evaluation is also a part of this combination Mr Shi lichen, founder of the third-party medical service system, pointed out that in foreign countries, when generic drugs come out, the original research drugs will definitely take the initiative to reduce their prices, while in China, the original research drugs will not reduce their prices even when they are due, and many of the original research drugs have not even entered the medical insurance, but the sales volume has been very good Despite the single digit growth of China's pharmaceutical industry in recent years, the performance of multinational pharmaceutical companies in China is still double-digit Growth This is actually related to doctors' medication habits and their confidence in generics If the quality of generic drugs is improved through consistency evaluation, the price of original research drugs will be reduced accordingly In addition, the state also regulates the profession of medical representatives and severely crack down on the sales with money Pharmaceutical enterprises need to guarantee the sales volume, and entering the medical insurance is an important way In many cases, entering the medical insurance must exchange the price for the quantity, and negotiate with the state on the price of drugs.